You searched for "presentation"
LUTS update
Case study A 70-year-old, generally fit and well male attends your outpatient clinic. He has experienced a gradual deterioration in his voiding over the last few months. Specifically, he reports hesitancy, poor flow and nocturia. He denies visible haematuria. His...
Robot assisted radical prostatectomy – could it be gold standard?
Prostate cancer (PCa) is still the second leading cause of cancer-related death in men in the United States. Most of the PCa are organ confined at the time of diagnosis. To watch (observation / active surveillance) or fry (radiotherapy) or...‘No Deal’ Brexit – how might it impact urological practice in the UK?
On 29 March 2017, the Government of the United Kingdom of Great Britain & Northern Ireland triggered Article 50 of the Lisbon Treaty, formally starting the two-year period for talks with the European Union (EU) in which to reach a...Biomarkers in prostate cancer detection
Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...Demanding cases or nightmares in endourology? Jan/Feb 2016
The second article in this series of challenging cases in endourology describes some stent-related problems. Case 1 A 76-year-old male with end stage renal failure due to obstructive uropathy from benign prostatic enlargement was transferred from a referring hospital. A...Ambulatory local anaesthetic implantation of percutaneous sacral nerve stimulators
Background The current treatment paradigm for detrusor overactivity (DO) and dysfunctional voiding (DV) includes conservative measures, pharmacotherapy, intravesical onabotulinum toxin A (Botox®), sacral nerve modulation (SNM / SNS) and urinary diversion as a last resort [1]. Incidence of DO is...
Risk factors for BC after minimally invasive RNU
Bladder cancer (BC) after radical nephroureterectomy (RNU) has an approximate incidence of 20-50%. This contemporary multicentre study will inform the ongoing debate on risk factors for BC after minimally invasive RNU and how it may be prevented. Three hundred and...
Morbidity and mortality after surgery for LUTS
The market for bladder outflow obstruction surgery is currently wide open with new technologies such as Urolift® emerging. One of the key selling points of new technologies is the comparative safety and efficacy compared to traditional techniques such as transurethral...
ABU joins BCG in fight against NMIBC recurrence?
The authors test a hypothesis retrospectively in two cohorts of patients with non-muscle invasive bladder cancer (NMIBC), that endogenous bacteria in the bladder might exert antitumour effects, similar to live mycobacteria (BCG), through local immune-related or other mechanisms, on NMIBC...
RCC recurrence rates post laparascopic partial nephrectomy
In recent years laparascopic partial nephrectomy (LPN) has emerged as an oncologically safe alternative to its radical nephrectomy counterpart. There is however a lack of consensus amongst the urology community regarding surveillance after LPN for patients with stage I tumours....
Has laparoscopic radical prostatectomy had its day?
Over recent years there has been a massive uptake in robotic surgery particularly for robot-assisted prostatectomy. The drive for this has been patient and physician led with little in the way of prospective randomised trials showing benefits over established operative...
